Table 3.
Everolimus pharmacokinetic variables during concomitant treatment with either 80 mg fluvastatin or 20 mg rosuvastatin daily. All variables except Tmax were ln-transformed before statistical analysis with paired Student's t-test. Tmax was analyzed with Wilcoxon signed rank test. Data are presented as mean (SD).
| Everolimus + fluvastatin | Everolimus + rosuvastatin | Ratio | P-value | |
|---|---|---|---|---|
| AUC0-12 (μg*h/L) | 80.3 (21.3) | 78.5 (21.9) | 0.98 | 0.61 |
| Cmax (μg/L) | 15.6 (7.48) | 16.2 (7.37) | 1.05 | 0.39 |
| CL/F (L/h) | 16.5 (8.52) | 17.4 (7.53) | 1.08 | 0.25 |
| T1/2 (h) | 20.4 (9.63) | 19.9 (7.47) | 1.02 | 0.42 |
| Tmax (h) | 0.79 (0.26) | 0.69 (0.28) | 0.96 | 0.37 |
| C0 (μg/L) | 4.54 (1.19) | 4.69 (0.96) | 1.05 | 0.35 |
AUC0-12, area under the plasma concentration versus time curve from zero to 12 hours; Cmax, maximum plasma concentrations; T1/2, half-life; Tmax, time to Cmax; C0, concentrations before the dose.